Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
Purple Biotech (NASDAQ/TASE: PPBT) reported positive interim data from its Phase 2 study of CM24, its lead oncology therapeutic candidate, for pancreatic ductal adenocarcinoma (PDAC) treatment. Key findings include:
1. High CEACAM1 and low PDL1 expression in tumors associated with improved overall survival (OS).
2. Improved OS for patients with serum neutrophil extracellular trap (NET) marker myeloperoxidase (MPO).
3. NETs proposed as a novel mechanism of action and potential biomarker for CM24-based therapy.
4. Data supports potential for biomarker-led studies and exploration of CM24's efficacy in other cancers.
The study evaluates CM24 combined with nivolumab and chemotherapy as a second-line PDAC treatment. Topline data expected in Q4 2024.
Purple Biotech (NASDAQ/TASE: PPBT) ha riportato dati intermedi positivi dal suo studio di Fase 2 su CM24, il suo candidato terapeutico principale per il trattamento dell'adenocarcinoma duttale pancreatico (PDAC). I risultati chiave includono:
1. Alta espressione di CEACAM1 e bassa espressione di PDL1 nei tumori associata a una maggiore sopravvivenza globale (OS).
2. Miglioramento della OS per i pazienti con il marcatore di neutrofili extracellulari nel siero (NET) mieloperossidasi (MPO).
3. Proposta degli NET come un nuovo meccanismo d'azione e potenziale biomarcatore per la terapia basata su CM24.
4. I dati supportano il potenziale per studi basati su biomarcatori e l'esplorazione dell'efficacia di CM24 in altri tumori.
Lo studio valuta CM24 combinato con nivolumab e chemioterapia come trattamento di secondo livello per il PDAC. I dati principali sono attesi nel quarto trimestre del 2024.
Purple Biotech (NASDAQ/TASE: PPBT) reportó datos interinos positivos de su estudio de Fase 2 sobre CM24, su candidato terapéutico principal para el tratamiento del adenocarcinoma ductal pancreático (PDAC). Los hallazgos clave incluyen:
1. Alta expresión de CEACAM1 y baja expresión de PDL1 en tumores asociada con una mejora en la supervivencia general (OS).
2. Mejora de la OS para pacientes con el marcador de trampas extracelulares de neutrófilos (NET) mieloperoxidasa (MPO).
3. Se proponen los NET como un nuevo mecanismo de acción y biomarcador potencial para la terapia basada en CM24.
4. Los datos respaldan el potencial para estudios guiados por biomarcadores y la exploración de la eficacia de CM24 en otros cánceres.
El estudio evalúa CM24 combinado con nivolumab y quimioterapia como tratamiento de segunda línea para el PDAC. Se esperan datos preliminares en el cuarto trimestre de 2024.
Purple Biotech (NASDAQ/TASE: PPBT)는 췌장관 선암(PDAC) 치료를 위한 주요 항암 치료 후보인 CM24에 대한 2상 연구에서 긍정적인 중간 데이터를 보고했습니다. 주요 발견 사항은 다음과 같습니다:
1. 높은 CEACAM1 발현과 낮은 PDL1 발현이 전체 생존율(OS) 향상과 연관되어 있습니다.
2. 혈청 중성구 세포외 덫(NET) 지표인 미엘로페록시다아제(MPO)에 대해 향상된 OS.
3. NET이 CM24 기반 요법의 새로운 작용 메커니즘 및 잠재적 바이오마커로 제안됨.
4. 데이터는 바이오마커 주도 연구 및 다른 암에서 CM24의 효능 탐색의 가능성을 지원합니다.
이번 연구는 PDAC의 2차 치료제로서 CM24를 니볼루맙 및 화학요법과 병합하여 평가합니다. 주요 데이터는 2024년 4분기에 발표될 예정입니다.
Purple Biotech (NASDAQ/TASE: PPBT) a rapporté des données intermédiaires positives de son étude de Phase 2 sur CM24, son principal candidat thérapeutique en oncologie pour le traitement de l'adénocarcinome canalaire pancréatique (PDAC). Les résultats clés incluent :
1. Une forte expression de CEACAM1 et une faible expression de PDL1 dans les tumeurs associée à une amélioration de la survie globale (OS).
2. Amélioration de la OS pour les patients avec le marqueur sanguin NET myéloperoxydase (MPO).
3. Proposition des NET comme nouveau mécanisme d'action et biomarqueur potentiel pour la thérapie basée sur CM24.
4. Les données soutiennent le potentiel d'
L'étude évalue CM24 en combinaison avec le nivolumab et la chimiothérapie en tant que traitement de seconde ligne pour le PDAC. Les résultats principaux sont attendus au quatrième trimestre 2024.
Purple Biotech (NASDAQ/TASE: PPBT) berichtete von positiven Zwischenresultaten aus seiner Phase-2-Studie zu CM24, dem führenden onkologischen Therapeutikum für die Behandlung von duktalem Pankreasadenokarzinom (PDAC). Die wichtigsten Ergebnisse umfassen:
1. Hohe CEACAM1- und niedrige PDL1-Expression in Tumoren, die mit einer verbesserten Gesamtüberlebensrate (OS) verbunden sind.
2. Verbesserte OS für Patienten mit dem Serum-Marker für neutrophile extrazelluläre Fallen (NET) Myeloperoxidase (MPO).
3. NETs werden als neuartiger Wirkmechanismus und potenzieller Biomarker für die CM24-basierte Therapie vorgeschlagen.
4. Die Daten unterstützen das Potenzial für biomarkerbasierte Studien und die Erforschung der Wirksamkeit von CM24 bei anderen Krebsarten.
Die Studie bewertet CM24 in Kombination mit Nivolumab und Chemotherapie als Second-Line-Behandlung für PDAC. Wichtige Daten werden im vierten Quartal 2024 erwartet.
- Improved overall survival (OS) for patients with high CEACAM1 and low PDL1 expression (HR=0.1, 4.1 months prolongation in median OS, p=0.01)
- Potential 62% reduction in risk of death (HR=0.38) for patients with serum MPO levels < 350 ng/mL
- CM24 inhibits NET-induced platelet aggregation, potentially reducing cancer-associated thrombosis
- Identification of potential biomarkers for patient selection, improving treatment outcomes
- Improvement in OS, progression-free survival (PFS), and objective response rate (ORR) in the experimental arm compared to standard of care
- Larger sample size required to confirm results and define cutoff values for biomarkers
- Study still ongoing, with topline data not expected until Q4 2024
The interim data from Purple Biotech's Phase 2 study of CM24 in pancreatic ductal adenocarcinoma (PDAC) is highly promising. The identification of potential biomarkers - high CEACAM1, low PDL1 and serum NET marker MPO - could be game-changing for patient selection and treatment efficacy. The combination of high CEACAM1 and low PDL1 showed a remarkable
This interim data significantly strengthens Purple Biotech's position in the competitive oncology market. The potential for a serum biomarker (MPO) for patient selection is particularly valuable, as it could lead to more efficient clinical trials and faster market adoption if CM24 is approved. The data suggesting efficacy in patients with low PDL1 expression opens up a substantial market opportunity, as these patients typically don't respond well to current immunotherapies. However, investors should note that this is still interim data from a Phase 2 trial. The crucial test will be the topline data expected in Q4 2024. If positive, it could catalyze significant interest from big pharma for potential partnerships or acquisitions, given the unmet need in PDAC treatment.
The biomarker findings in this Phase 2 study are exceptionally valuable for future trial design. The ability to potentially select patients based on CEACAM1, PDL1 expression and serum MPO levels could lead to more targeted and efficient Phase 3 trials. This approach aligns with the growing trend towards precision medicine in oncology. The multi-center nature of the trial (18 centers across the U.S., Spain and Israel) adds robustness to the data. However, the sample size of 63 patients is relatively small. While the results are encouraging, they will need validation in a larger cohort. The planned topline data in Q4 2024 will be important in determining whether these biomarker findings hold up in the full patient population and whether they translate into clinically meaningful outcomes.
- High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients (HR=0.1 and prolongation of 4.1 months in median OS, p value 0.01, for the combination), which support the CM24/nivolumab combined treatment.
- Improved OS is demonstrated for patients with serum neutrophil extracellular trap (NET) marker myeloperoxidase (MPO) (HR=0.38 and prolongation of 3.3 months in median OS, p value 0.1), similar trend for NET positive tumors.
- The results presented in the poster propose NETs as a novel MoA and a potential biomarker for CM24-based therapy.
- New biomarker data supports the potential for future biomarker-led studies and exploration of CM24’s efficacy in other cancers where the CEACAM1 novel target plays a key role in cancer progression and immune evasion
REHOVOT, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today reported new positive biomarker findings for its lead oncology therapeutic candidate CM24. These data were presented yesterday at the American Association for Cancer Research® (AACR) Special Conference on Advances in Pancreatic Cancer Research currently ongoing in Boston, in a poster titled, “Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer”.
“We are excited to present additional positive interim data from our Phase 2 study with CM24. CEACAM1 as a novel target in oncology continues to be supported by these data, underscoring its potential given its high expression on cancer cells, tumor infiltrating leucocytes and on NETs, suggesting the potential multiple roles of CM24 in overcoming immune evasion,” stated Purple Biotech CEO Gil Efron. “Moreover, these data enable us to potentially design biomarker- guided studies for CM24 for the treatment of pancreatic ductal adenocarcinoma (PDAC), as well as other cancers.”
Purple Biotech’s Phase 2 study is evaluating CM24 in combination with Bristol Myers Squibb's PD-1 inhibitor nivolumab plus standard of care (SoC) chemotherapy as a second line treatment of patients with PDAC and compared to SoC chemotherapy alone. Sixty-three patients have been enrolled in the randomized study across 18 centers in the U.S., Spain, and Israel.
The following is a summary of findings presented in the poster:
Mechanism of Action
CM24 blocks CEACAM1 interactions, which have key roles in cancer progression, immune escape and metastasis. CEACAM1 is part of the NET complex, involved in tumor immune evasion, metastasis and cancer-associated thrombosis, affecting patient survival. Purple Biotech has previously presented data that demonstrates that CM24 binds to CEACAM1 on NETs, suppresses NET-induced migration of cancer cells and inhibits in-vivo tumor metastasis. In the poster, Purple Biotech presents data that demonstrates that CM24 also inhibits NET-induced platelet aggregation, an in-vitro assay imitating the thrombosis process.
CM24+nivolumab+Nal-IRI/5FU/LV treatment of PDAC patients reduced serum levels of the NET marker, MPO, and showed potential overall survival (OS) benefit to patients with reduced post-dose MPO as compared to the control arm.
NET Marker MPO as a Potential Serum Biomarker for Patient Selection for CM24-Based Therapy
An analysis of patients with serum MPO levels < 350 ng/mL, demonstrated a potential
High Tumor CEACAM1 & Low PDL1 as Potential Biomarkers for CM24-Based Therapy
An analysis of patients with high CEACAM1+tumor cells (H-score > 115) or low PDL1 (CPS ≤ 1) demonstrated a potential
Combining these two potential biomarkers, suggests augmented outcome of
“A serum biomarker for patient selection is a major advantage for cancer patients in general and PDAC patients in particular. The additional interim data suggesting serum NET levels as a potential biomarker for improving the outcome of CM24-based therapy, together with the ability of this therapy to reduce serum NET levels in PDAC patients and to inhibit NET-related activities in vitro, add supporting evidence for NETs as a new mechanism of action (MoA) and potential biomarker for CM24-based therapy,” said Dr. Hadas Reuveni, VP R&D of Purple Biotech. “Additional encouraging results suggesting that the CM24/ nivolumab/chemotherapy effect is most pronounced among patients with high CEACAM1 expression and low PDL1 also relate to the CM24/nivolumab MoA and support the CM24/nivolumab combined treatment. This may open a new opportunity for patients who are not eligible for anti-PD1 therapy in various indications. A larger sample size is required to confirm the results and better define the cutoff values.”
Interim data from Purple Biotech’s Phase 2 study presented in June at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated improvement in OS, progression free survival (PFS), objective response rate (ORR) and all other efficacy endpoints in the CM24+nivolumab+Nal-IRI/5FU/LV experimental arm as compared with the SoC control arm. Topline data are expected in the fourth quarter of 2024.
The poster is available on the Publications section of Purple Biotech’s website and in the following link: https://purple-biotech.com/pipeline/#1Publications
About Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes CM24, NT219 and IM1240. CM24 is a humanized monoclonal antibody that blocks CEACAM1, that supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. As a proof of concept of these novel pathways, the Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second line patients with recurrent and/or metastatic SCCHN (R/N SCCHN). The Company is advancing CAPTN-3, a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets 5T4 expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.
Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219, CM24 and IM1240; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2023 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.
CONTACTS:
Company Contact:
Lior Fhima
Chief Financial Officer
IR@purple-biotech.com
FAQ
What are the key findings of Purple Biotech's Phase 2 study for CM24 in PDAC treatment?
How does CM24 potentially improve survival in PDAC patients?
What is the significance of the biomarker findings for PPBT's CM24 therapy?
When are the topline results expected for Purple Biotech's Phase 2 study of CM24?
